Balanced news tone
News Sentiment
SLBT sentiment intelligence
SL Science Holding Limited Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
76/100 classification confidence.
directly relevant articles
high-authority source matches
-9.1% over one week, -25.7% over four weeks, trend inactive, and near fair-value range.
Free cash flow of SL Science Holding Limited – NASDAQ:SLBT
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Free cash flow of SL Science Holding Limited – NASDAQ:SLBT
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 22 Jul 2026 20:12
- Source
- TradingView
SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 12:00
- Source
- GlobeNewswire
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 07:00
- Source
- Market source
Price to cash flow ratio of SL Science Holding Limited – NASDAQ:SLBT
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 12 Jul 2026 10:59
- Source
- TradingView
Non-controlling/minority interest of SL Science Holding Limited – NASDAQ:SLBT
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 09:11
- Source
- TradingView
Net debt of SL Science Holding Limited – NASDAQ:SLBT
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 11 Jul 2026 10:58
- Source
- TradingView
Diluted earnings per share (diluted EPS) of SL Science Holding Limited – NASDAQ:SLBT
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 Jul 2026 02:56
- Source
- TradingView
Discontinued operations of SL Science Holding Limited – NASDAQ:SLBT
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 02:49
- Source
- TradingView
After tax other income/expense of SL Science Holding Limited – NASDAQ:SLBT
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 02:49
- Source
- TradingView
Operating income of SL Science Holding Limited – NASDAQ:SLBT
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 02:25
- Source
- TradingView
Cost of goods sold of SL Science Holding Limited – NASDAQ:SLBT
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 02:25
- Source
- TradingView
EBIT of SL Science Holding Limited – NASDAQ:SLBT
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 22:40
- Source
- TradingView
SL Science Holding Limited Cash Flow – NASDAQ:SLBT
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 10 Jul 2026 19:21
- Source
- TradingView
SL Science Holding Limited Statistics – NASDAQ:SLBT
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 17:59
- Source
- TradingView
SL Science Holding Limited Financial Statements – NASDAQ:SLBT
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 17:29
- Source
- TradingView
SL Science Submits Orphan Drug Designation Request to FDA for GDT Cell Therapy in Glioblastoma
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 12:20
- Source
- MT Newswires
SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 12:00
- Source
- GlobeNewswire
SL Science Holding Limited Reports Full Year 2025 Financial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 21:13
- Source
- GlobeNewswire
SL Science’s 2025 revenue fell 35% as R&D spending held at $2.07M
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
[6-K] SL Science Holding Ltd Current Report (Foreign Issuer) | SLBT SEC Filing - Form 6-K
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Stock Titan
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView